Pristimerin ameliorates spasmolytic polypeptide-expressing metaplasia by modulating <i>Cdkn1c</i> (p57)-mediated glycolytic reprogramming
Pristimerin effectively ameliorates gastric mucosal pathological damage and oxyntic atrophy in high-dose tamoxifen-induced SPEM mice, and improves SPEM progression by modulating <i>Cdkn1c</i> (p57)-mediated glycolytic reprogramming.
Authors
- Ziwei Pan (ORCID: https://orcid.org/0000-0002-9529-4448)
- Xue-Dan Yao
- Yan-Qing Liu
- Jun-Song Wen
- Yao-Dong Zhu
Institutions
- Anhui Medical University (CN)
- Anhui University of Traditional Chinese Medicine (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- Yangzhou University (CN)
Publication Details
- Journal
- World Journal of Gastroenterology
- Published
- 2026-03-02
- DOI
- https://doi.org/10.3748/wjg.v32.i10.113771
- Primary Topic
- Natural Compounds in Disease Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00